Cargando…
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience
Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two pati...
Autores principales: | Tahover, Esther, Bar-Shalom, Rachel, Sapir, Eli, Pfeffer, Raphael, Nemirovsky, Igor, Turner, Yehonatan, Gips, Maya, Ohana, Patricia, Corn, Benjamin W., Wang, Andrew Z., Gabizon, Alberto A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275313/ https://www.ncbi.nlm.nih.gov/pubmed/30534533 http://dx.doi.org/10.3389/fonc.2018.00544 |
Ejemplares similares
-
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
por: Golan, Talia, et al.
Publicado: (2015) -
Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes
por: Gabizon, Alberto, et al.
Publicado: (2023) -
Characterization of a Mesoporous Silica Nanoparticle Formulation Loaded with Mitomycin C Lipidic Prodrug (MLP) and In Vitro Comparison with a Clinical-Stage Liposomal Formulation of MLP
por: Manzano, Miguel, et al.
Publicado: (2022) -
Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome
por: Zhang, Huiyun, et al.
Publicado: (2022) -
PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)